Hoya recently unveiled results of a six-year follow-up clinical study on its MiYOSMART lens, marking the longest study on a myopia management spectacle lens.
It builds on an original two-year, double-blind randomised trial1 concluding that children aged 8-13 years wearing MiYOSMART had 60% less myopia progression compared with single-vision wearers as measured by the axial elongation, and a 59% reduction in spherical equivalent refraction. Subsequent three-year data2 showed the lens continued to slow myopia progression, while patients who switched from single-vision to MiYOSMART had a significant slowdown in their condition.
The new six-year data involved 90 children in Asia. Importantly, the company reported MiYOSMART’s myopia control effect was sustained over time. It also confirmed patients who stopped wearing the lens showed no rebound effects compared to the initial myopia rates of progression during the two-year randomised control trial or with the general population. And the average cumulative myopia progression was less than 1.00 D and axial elongation 0.6 mm over six years in the MiYOSMART group.3
References
1. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739
2. Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. British Journal of Ophthalmology Published Online First: 17 March 2021. doi: 10.1136/bjophthalmol-2020-317664
3. Lam CSY, Tang WC, Zhang A, Tse D, To CH. Myopia control in children wearing DIMS spectacle lens: 6 years results. ARVO 2022 Annual Meeting, May 1-4, Denver, US.
